Pharma

The Readout Damian Garde

STAT Plus: Beam is trading like it’s 2021

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about the FTC vs. PBMs, FDA adcomm voting and more

Pharmalot Ed Silverman

STAT Plus: FTC says pharmacy benefit managers are stonewalling requests for information

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about Congress punts PBM reform, another obesity drug and more

The Readout Meghana Keshavan

STAT Plus: GSK pill works in uncomplicated gonorrhea

The Readout Damian Garde

STAT Plus: The FDA isn’t afraid to yank a disappointing drug

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about state moves on drug pricing, an asthma med for kids and more

Pharma Andrew Joseph

STAT Plus: Obesity treatment from Boehringer Ingelheim, Zealand Pharma succeeds in study in liver condition MASH

Pharma Elaine Chen

STAT Plus: Liver disease MASH is next target for obesity drugs in development

Pharmalot Ed Silverman

STAT Plus: Oregon suspends a portion of its drug transparency law found to be unconstitutional

Pharmalot Rachel Cohrs and Ed Silverman

STAT Plus: Amgen’s rheumatoid arthritis drug Enbrel targeted for first-in-the-nation price limit in Colorado

Pharmalot Ed Silverman

STAT Plus: Up and down the ladder: The latest comings and goings

Pharma Ed Silverman

STAT Plus: Pharmalittle: We’re reading about a pharma job slowdown, diet drugs boosting GDP, and more

The Readout Meghana Keshavan

STAT Plus: What do CEOs owe the world?

Pharmalot Ed Silverman

STAT Plus: FDA gives a mixed response to a petition seeking greater clinical trial transparency

The Readout Damian Garde

STAT Plus: Novavax’s money is going in the wrong direction

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about India-made versions of Wegovy, an RSV vaccine scramble, and more

Pharmalot Ed Silverman

STAT Plus: Novavax and Gavi end a bitter dispute over Covid-19 vaccines with a refund up to $475 million

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about a CEO change at AbbVie, a long-acting HIV drug, and more

The Readout Damian Garde

STAT Plus: Actually Wegovy is good for dialysis companies, dialysis provider says

Pharma Matthew Herper

STAT Plus: AbbVie CEO Gonzalez to step down after a decade fiercely defending its top seller, Humira

The Readout Damian Garde

STAT Plus: Bayer, short on cash, reaches into shareholders’ pockets

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about weight loss drugs, a cell therapy for melanoma, and more

Pharmalot Ed Silverman

STAT Plus: A lawsuit over a controversial Sanofi drug shortage is unexpectedly revived

Pharmalot Ed Silverman

STAT Plus: Up and down the ladder: The latest comings and goings

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about kids taking Wegovy, telehealth for abortion pills, and more

The Readout Damian Garde

STAT Plus: Alnylam thickened the plot

Pharmalot Ed Silverman

STAT Plus: Hospital claims it was ‘drastically’ overcharged by pharma in a federal drug discount program

The Readout Damian Garde

STAT Plus: Pharma’s contractors might finally be on the rebound